

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Exagen Diagnostics, Inc.		10/12/2010	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Cypress Bioscience, Inc.		
Street Address:	4350 Executive Drive, Suite 325		
City:	San Diego		
State/Country:	CALIFORNIA		
Postal Code:	92121		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	77551794	AVISE	
Serial Number:	77567183	AVISE MCV	
Serial Number:	77567161	AVISE PG	
CORRESPONDENCE DATA			
Fax Number:	(415)693-2222		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	4156932440		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		
Address Line 1:	101 California Street, 5th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
ATTORNEY DOCKET NUMBER:	CYPRESS/EXAGEN 093330-129		
NAME OF SUBMITTER:	C. Rhem		
Signature:	/CR/		

CH \$90.00 77551794

900173780

TRADEMARK
REEL: 004294 FRAME: 0916

Date:

10/12/2010

Total Attachments: 32

source=Cypress IPSA#page1.tif
source=Cypress IPSA#page2.tif
source=Cypress IPSA#page3.tif
source=Cypress IPSA#page4.tif
source=Cypress IPSA#page5.tif
source=Cypress IPSA#page6.tif
source=Cypress IPSA#page7.tif
source=Cypress IPSA#page8.tif
source=Cypress IPSA#page9.tif
source=Cypress IPSA#page10.tif
source=Cypress IPSA#page11.tif
source=Cypress IPSA#page12.tif
source=Cypress IPSA#page13.tif
source=Cypress IPSA#page14.tif
source=Cypress IPSA#page15.tif
source=Cypress IPSA#page16.tif
source=Cypress IPSA#page17.tif
source=Cypress IPSA#page18.tif
source=Cypress IPSA#page19.tif
source=Cypress IPSA#page20.tif
source=Cypress IPSA#page21.tif
source=Cypress IPSA#page22.tif
source=Cypress IPSA#page23.tif
source=Cypress IPSA#page24.tif
source=Cypress IPSA#page25.tif
source=Cypress IPSA#page26.tif
source=Cypress IPSA#page27.tif
source=Cypress IPSA#page28.tif
source=Cypress IPSA#page29.tif
source=Cypress IPSA#page30.tif
source=Cypress IPSA#page31.tif
source=Cypress IPSA#page32.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "*IP Agreement*") is made as of the 12th day of October, 2010 by and between **EXAGEN DIAGNOSTICS, INC.**, a Delaware corporation ("*Grantor*"), and **CYPRESS BIOSCIENCE, INC.**, a Delaware corporation ("*Secured Party*").

RECITALS

Grantor has agreed to purchase the Assets from the Secured Party pursuant to that certain Asset Purchase Agreement dated as of October 8, 2010 among Grantor, Secured Party and Proprius, Inc., a Delaware corporation ("*Proprius*"), as amended from time to time (as amended, the "*Purchase Agreement*"). The closing of the transactions contemplated by the Purchase Agreement is contingent upon the execution and delivery of this IP Agreement. Secured Party and Proprius are willing to enter into the Purchase Agreement with Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in certain patents, patent applications and other assets, to secure the payment and performance when due of Grantor's obligation under Section 1.3(c) of the Purchase Agreement (including to the extent payment of such obligation is accelerated pursuant to Section 1.9(a) of the Purchase Agreement), and, to the extent payment of such obligation is not made when due, interest payable on the amount owed pursuant to Section 1.11 of the Purchase Agreement (the "*Secured Obligation*"). Defined terms used but not defined herein shall have the same meanings as in the Purchase Agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows:

Effective as of the Closing Date, Grantor does hereby grant to Secured Party a continuing security interest of first priority in all of Grantor's right, title and interest in, to and under the following registered and unregistered intellectual property collateral, whether now or hereafter existing, and any and all proceeds thereof, as security for the prompt and complete payment and performance when due of the Secured Obligation (all of which shall collectively be called the "*Intellectual Property Collateral*"):

- (a) all Patents listed on Schedule A hereto;
- (b) all Trademarks listed on Schedule B hereto;
- (c) all patents and patent applications licensed to Grantor pursuant to that certain Exclusive License Agreement by and between the University of Pittsburgh – of the Commonwealth System of Higher Education and Stagemark, Inc. (and its successors and assigns) dated as of October 11, 2005 and as subsequently amended (the "*Pittsburgh License*")

and listed on Schedule C hereto and all other intellectual property licensed to Grantor pursuant to the Pittsburgh License;

(d) all patents and patent applications licensed to Grantor pursuant to that certain Exclusive License Agreement by and between Leiden University Medical Center and Proprius Pharmaceuticals, Inc. (and its successors and assigns) dated as of September 1, 2006 and as subsequently amended (the "**LUMC License**") and listed on Schedule D hereto and all other intellectual property licensed to Grantor pursuant to the LUMC License;

(e) all patents and patent applications licensed to Grantor pursuant to that certain License Agreement by and between Orgentec Diagnostika GmbH and Proprius, Inc. (and its successors and assigns) dated as of February 19, 2008 and as subsequently amended (the "**Orgentec License**") and listed on Schedule E hereto and all other intellectual property licensed to Grantor pursuant to the Orgentec License;

(f) all patents and patent applications licensed to Grantor pursuant to (i) the License Agreement by and between Prometheus Laboratories Inc. and Proprius, Inc. (and its successors and assigns) dated as of September 13, 2007 and as subsequently amended (the "**9/13 Prometheus License**") and (ii) the Sublicense Agreement by and between Prometheus Laboratories Inc. and Proprius, Inc. (and its successors and assigns) dated as of September 13, 2007 and as subsequently amended (the "**9/13 Prometheus Sublicense**") and listed on Schedule F hereto and all other intellectual property licensed to Grantor pursuant to any of the 9/13 Prometheus License and the 9/13 Prometheus Sublicense;

(g) any and all claims and causes of action for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) all amendments, extensions, renewals and extensions of any of the Patents, Trademarks, patents, patent applications or other intellectual property rights referenced above; and

(i) all proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the closing of the transactions contemplated by the Purchase Agreement. Upon (i) the failure of Grantor to satisfy the Secured Obligation when due, and for so long as such failure continues, or (ii) upon the occurrence and during the continuance of a Trigger Event, Secured Party shall have the right to exercise all the remedies of a secured party under the Code (as defined below). Grantor will pay any expenses (including reasonable attorney's fees) incurred by Secured Party in connection with the exercise of any of Secured Party's rights hereunder, including without limitation any expense incurred in disposing of the Intellectual Property Collateral. All of Secured Party's rights and remedies with respect to the Intellectual Property Collateral shall be cumulative. For purposes of this IP

Agreement, "Code" means the New York Uniform Commercial Code, as in effect from time to time; provided, however, that in the event that, by reason of mandatory provisions of any law, any or all of the attachment, perfection, priority, or remedies with respect to Secured Party's security interest in any Intellectual Property Collateral is governed by the Uniform Commercial Code as enacted and in effect in a jurisdiction other than the State of New York, the term "Code" shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies.

Notwithstanding the foregoing, the grant, assignment and transfer of a security interest as provided herein shall not extend to, and the term "Intellectual Property Collateral" shall not include "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise.

The provisions of this IP Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither this IP Agreement nor any rights or obligations hereunder may be assigned, sold or otherwise disposed of or transferred in whole or in part by any party, by operation of law or otherwise, without the prior written consent of the other party.

This IP Agreement shall be governed by and construed, interpreted and enforced in accordance with the laws of the State of New York, as applied to agreements executed and performed entirely in New York, without giving effect to the principles of conflicts of law thereof other than Section 5-1401 of the General Obligations Law of the State of New York.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties have caused this IP Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

SECURED PARTY:

EXAGEN DIAGNOSTICS, INC.

CYPRESS BIOSCIENCE, INC.

By: 

By: _____

Name: Scott L. Glenn

Name: Jay D. Kranzler

Title: Chairman and Chief Executive Officer

Title: Chairman and Chief Executive Officer

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

TRADEMARK
REEL: 004294 FRAME: 0921

IN WITNESS WHEREOF, the parties have caused this IP Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


GRANTOR:

SECURED PARTY:

EXAGEN DIAGNOSTICS, INC.

CYPRESS BIOSCIENCE, INC.

By: _____

By:  _____

Name: Scott L. Glenn

Name: Jay D. Kranzler

Title: Chairman and Chief Executive Officer

Title: Chairman and Chief Executive Officer

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

TRADEMARK
REEL: 004294 FRAME: 0922

SCHEDULE A

Cooley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-044/00US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/074,532	Jun-20-2008			EXPIRED
CYPR-044/01US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/218,796	Jun-19-2009			EXPIRED
CYPR-044/02US	MARKERS ASSOCIATED WITH METHOTREXATE THERAPY	61/356,770	Jun-21-2010			PENDING
CYPR-035/00US	METHODS FOR QUANTIFYING METHOTREXATE POLYGLUTAMATES USING TANDEM MASS SPECTROMETRY	61/058,849	Jun-04-2008			EXPIRED
CYPR-027/00US	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	61/047,094	Apr-22-2008			EXPIRED
CYPR-027/01US	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	12/428,299	Apr-22-2009	20090265116	Oct-22-2009	PENDING
CYPR-027/01WO	PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	PCT/US2009/041443	Apr-22-2009			NATIONAL PHASE DUE 10/22/2010
CYPR-047/00US CELLATOPE	IMPROVEMENTS IN METHODS FOR CALIBRATION OF DIAGNOSTIC INSTRUMENTATION	60/995,712	Sep-27-2007			EXPIRED

Cooley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-047/01US CELLATOPE	IMPROVED BUFFER COMPOSITIONS FOR DIAGNOSTIC ASSAYS	60/995,714	Sep-27-2007			EXPIRED
CYPR-047/02US CELLATOPE	COMPOSITIONS FOR USE AS DIAGNOSTIC ASSAY CONTROLS AND METHODS FOR PRODUCING SAME	60/995,716	Sep-27-2007			EXPIRED
CYPR-047/03US	METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS	12/748,060	Mar-26-2010			PENDING
CYPR-051/00US	PREDISPOSING GENOTYPE COMBINATIONS IN FOLATE AND ADENOSINE BIOSYNTHESIS	61/174,682	May-01-2009			EXPIRED
CYPR-051/01US	METHODS FOR EVALUATING METHOTREXATE EFFICACY AND/OR TOXICITY	61/316,703	Mar-23-2010			PENDING


Cooley Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
CYPR-052/00US	CELL-BASED COMPLEMENT ACTIVATION PRODUCT ALGORITHM FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS	61/252,626	Oct-16-2009			PENDING
BISPHOSPHONATE CYPR-038/01US	COMPOSITIONS COMPRISING A BISPHOSPHONATE AND AN ANTIFOLATE	11/670,674	Feb-02-2007	20070225258	Sep-27-2007	PENDING Non-Final Rejection mailed May-25-2010; response due Aug-25-2010
SAM-E CYPR-043/00US	METHODS OF REDUCING MTX TOXICITY	61/136,081	Aug-11-2008			EXPIRED
CYPR-047/01WO	METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS	PCT/US2008/076302	Sep-12-2008			CLOSED

Grantor has co-ownership rights under the following patents and the security interest granted pursuant to this IP Agreement extends only to Grantor's ownership interest in such patents:

CYPR-048/00US CELLATOPE	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	61/105,865	Oct-16-2008			EXPIRED
CYPR-048/01US CELLATOPE	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	12/581,057	Oct-16-2009			PENDING
CYPR-048/01WO	METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES	PCT/US2009/061085	Oct-16-2009			NATIONAL PHASE DUE 4/16/2011

SCHEDULE B

TRADEMARK	COUNTRY	APP. NO./ FILING DATE	REG NO./ ISSUE DATE	GOODS/SERVICES	STATUS
<u>AVISE</u>	U.S.	7551794 August 20, 2008	N/A	<p>Class 42: Medical laboratory services, namely, laboratory testing, evaluation and research services; medical laboratory services, namely, disease management and pathology services; medical laboratory services, namely, providing medical laboratory information to health care providers, managed care providers and patients via global computer networks, medical and clinical chemical laboratory services used by medical professionals for diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring</p> <p>Class 44: Health care for treating rheumatological, neurological, immunological, oncological and hematological disorders and pain management; providing medical and health information on the treatment of rheumatological, neurological, immunological, oncological and hematological disorders and pain management</p>	<p>PENDING; ALLOWED</p> <p>Filed ITU application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 6, 2009; Statement of Use filed</p>
<u>AVISE MCV</u>	U.S.	77567183 September 10, 2008	N/A	<p>Class 42: Medical laboratory services, namely, laboratory testing, evaluation and research services; medical laboratory services, namely, disease management and pathology services; medical laboratory services, namely, providing medical laboratory information to health care providers, managed care providers and patients via global computer networks; medical and clinical chemical laboratory services used by medical professionals for diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring; medical laboratory</p>	<p>PENDING; ALLOWED</p> <p>Filed ITU application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 13, 2009; Statement of Use filed</p>

TRADEMARK	COUNTRY	APP. NO./ FILING DATE	REG NO./ ISSUE DATE	GOODS/SERVICES	STATUS
AVISE PG (Stylized) 	U.S.	77567161 September 10, 2008	N/A	antibody testing services for detecting mutated citrullinated vimentin; medical laboratory services for detecting, providing prognosis and monitoring rheumatoid arthritis disease in patients Class 44: Medical antibody testing services for detecting mutated citrullinated vimentin; medical testing services for detecting, providing prognosis and monitoring rheumatoid arthritis disease in patients	PENDING; ALLOWED Filed ITU application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 6, 2009; Statement of Use filed

SCHEDULE C

Attorney Docket No.	Title	Appln. No.	Filing Date	Patent No./Publication No.	Issue Date/Publication Date	Status
Klarquist 8123-83095-01-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	60/570,406	5/11/2004			Expired
Klarquist 8123-83095-02-PCT	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	PCT/US2005/016436	5/11/2005			National Filings in AU, CA, EP, JP
Klarquist 8123-83095-03-AU	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2005242719	5/11/2005			Pending
Klarquist 8123-83095-04-CA	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2,564,492	5/11/2005			Pending
Klarquist 8123-83095-05-EP	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	5747945.3	5/11/2005			Pending
Klarquist 8123-83095-06-JP	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	2007-513301	5/11/2005			Pending
Klarquist 8123-83095-07-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	10/545,052	10/10/2006	7,585,640	9/8/2009	Issued
Klarquist 8123-83095-08-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	11/127,348	5/11/2005			Pending
Klarquist 8123-83095-09-US	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	12/511,956	7/29/2009			Pending
Klarquist 8123-83095-11-EPC	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING	10005232.3	5/11/2005			REGISTERED Validated in Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Spain, Sweden, Switzerland, United Kingdom VALIDATED
Klarquist 8123-83095-12-BE	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING					VALIDATED
Klarquist 8123-	DIAGNOSING AND MONITORING					VALIDATED

83095-13-DK	INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-14-FI	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-15-FR	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-16-DE	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-17-IT	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-18-LU	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-19-NL	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-20-ES	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-21-SE	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-22-CH	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-23-GB	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83095-24-HK	DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING									VALIDATED
Klarquist 8123-83096-01-US	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (PROVISIONAL)							60/318,541	9/10/2001	Expired
Klarquist 8123-83096-02-PCT	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (PCT)							PCT/US2002/028910	9/9/2002	Completed
Klarquist 8123-83096-03-AU	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (AUSTRALIA)							2002323691	9/9/2002	2002323691 7/17/2008
Klarquist 8123-83096-04-CA	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (CANADA)							2,460,189	9/9/2002	Pending
Klarquist 8123-	DIAGNOSIS & MONITORING OF							2822148.6	9/9/2002	Abandoned

83096-05-CN	SYSTEMIC LUPUS (CHINA)	2757691.7	9/9/2002				Pending
Klarquist 8123-83096-06-EP	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (EUROPE)	722/CHENP/2004	9/9/2002				To be Abandoned
Klarquist 8123-83096-07-IN	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (INDIA)	2003-526353	9/9/2002				Pending
Klarquist 8123-83096-08-JP	SYSTEMIC LUPUS (JAPAN)	10/489,219	3/10/2004	7,390,631	6/24/2008		Issued
Klarquist 8123-83096-09-US	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (U.S. NATIONAL STAGE)	2008202941	7/3/2008				Pending
Klarquist 8123-83096-10-AU	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (AUSTRALIAN DIVISIONAL)	2009-197692	9/9/2002				Pending
Klarquist 8123-83096-11-JP	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (JAPAN DIVISIONAL)						VALIDATED
Klarquist 8123-83096-12-BE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (BELGIUM)						VALIDATED
Klarquist 8123-83096-13-DK	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (DENMARK)						VALIDATED
Klarquist 8123-83096-14-FI	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (FINLAND)						VALIDATED
Klarquist 8123-83096-15-FR	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (FRANCE)						VALIDATED
Klarquist 8123-83096-16-DE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (GERMANY)						VALIDATED
Klarquist 8123-83096-17-IT	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (ITALY)						VALIDATED
Klarquist 8123-83096-18-LU	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (LUXEMBOURG)						VALIDATED
Klarquist 8123-83096-19-NL	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (THE NETHERLANDS)						VALIDATED
Klarquist 8123-83096-20-NO	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (NORWAY)						VALIDATED
Klarquist 8123-83096-21-ES	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SPAIN)						VALIDATED
Klarquist 8123-83096-22-SE	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWEDEN)						VALIDATED
Klarquist 8123-83096-23-CH	DIAGNOSIS & MONITORING OF SYSTEMIC LUPUS (SWITZERLAND)						VALIDATED
Klarquist 8123-	DIAGNOSIS & MONITORING OF						VALIDATED

83096-24-GB	SYSTEMIC LUPUS (UNITED KINGDOM)								
Klarquist 8123-83097-01-US	DIAGNOSIS AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	60/463,447	4/16/2003						Expired
Klarquist 8123-83097-02-PCT	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (PCT)	PCT/US2004/011982	4/16/2004						Completed
Klarquist 8123-83097-03-AU	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	2004232007	4/16/2004						Pending
Klarquist 8123-83097-04-CA	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	2,522,261	4/16/2004						Pending
Klarquist 8123-83097-05-EPC	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (EPC)	4759986.5	4/16/2004						Pending
Klarquist 8123-83097-06-JP	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS (JAPAN)	2006-513114	4/16/2004						Pending
Klarquist 8123-83097-07-US	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	10/552,177	11/20/2006	7,588,905	9/15/2009				Issued
Klarquist 8123-Klarquist 83097-08-US	IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS	12/538,001	8/7/2009						Pending
Klarquist 8123-83100-01-US	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (US)	60/478,493	6/13/2003						Expired
Klarquist 8123-83100-02-PCT	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (PCT)	PCT/US2004/018552	6/12/2004						Entered National Phase
Klarquist 8123-83100-03-AU	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (AUSTRALIA)	2004249155	6/12/2004	2004249155					ISSUED
Klarquist 8123-83100-04-CA	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (CANADA)	2,529,045	6/12/2004						Pending.
Klarquist 8123-83100-05-EP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (EUROPE)	4776460	6/12/2004	1635692	4/21/2010				ISSUED

Klarquist 8123-83100-06-IN	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (INDIA)	132/CHENP/2006	6/12/2004			Abandoned
Klarquist 8123-83100-07-IS	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (ISRAELI)	172488	6/12/2004			Pending
Klarquist 8123-83100-08-JP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (JAPAN)	2006-533709	6/12/2004			Pending
Klarquist 8123-83100-09-KR	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (KOREA)	10-2005-7023932	6/12/2004			To Be Abandoned
Klarquist 8123-83100-10-NZ	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NEW ZEALAND)	544223	6/12/2004			To Be Abandoned
Klarquist 8123-83100-11-NO	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NORWAY)	20056013	6/12/2004			Pending
Klarquist 8123-83100-12-SA	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SOUTH AFRICA)	2005/10325	6/12/2004	2005/10325	4/30/2008	ISSUED
Klarquist 8123-83100-13-US	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (U.S.)	10/866,509	6/12/2004		10/29/2004	Pending
Klarquist 8123-83100-15-EPC	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (EPC)	10003328.1	6/12/2004			Pending
Klarquist 8123-83100-16-BE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (BELGIUM)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-17-DK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (DENMARK)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-18-FI	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND	4776460	6/12/2004	1635692	4/21/2010	Validated

Klarquist 8123-83100-19-FR	INFLAMMATORY DISEASES (FINLAND) MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (FRANCE)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-20-DE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (GERMANY)	4776460	6/12/2004	602004026724.4-08	4/21/2010	Validated
Klarquist 8123-83100-21-IT	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (ITALY)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-22-LU	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (LUXEMBOURG)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-23-NL	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (NETHERLANDS)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-25-ES	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SPAIN)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-26-SE	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SWEDEN)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-27-CH	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (SWITZERLAND)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-28-UK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (UK)	4776460	6/12/2004	1635692	4/21/2010	Validated
Klarquist 8123-83100-29-JP	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES (JAPAN)	2010-90939	6/12/2004			Pending
Klarquist 8123-83100-30-HK	MONITORING IMMUNOLOGIC, HEMATOLOGIC AND INFLAMMATORY DISEASES					Pending

Klarquist 8123-83101-01-US	(HONG KONG) REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS	60/560,986	4/9/2004				EXPIRED
Klarquist 8123-83101-02-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS	60/579,621	6/14/2004				EXPIRED
Klarquist 8123-83101-03-PCT	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (PCT)	PCT/US2005/011914	4/8/2005				NATIONAL PHASE FILINGS-AU, CA, EP, JP
Klarquist 8123-83101-04-AU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (AUSTRALIA)	2005241415	4/8/2005				Pending
Klarquist 8123-83101-05-CA	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (CANADA)	2,561,684	4/8/2005				Pending
Klarquist 8123-83101-06-EP	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (EUROPE)	5776689.1	4/8/2005	1756571	8/18/2010		ISSUED
Klarquist 8123-83101-07-JP	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (JAPAN)	2007-507524	4/8/2005				Pending
Klarquist 8123-83101-08-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	11/101,898	4/8/2005	7,361,517	4/22/2008		ISSUED
Klarquist 8123-83101-09-US	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (U.S.)	11/845,365	8/27/2007				Abandoned
Klarquist 8123-83101-10-BE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (BELGIUM)	5776689.1	4/8/2005	1756571	8/18/2010		Validated
Klarquist 8123-83101-11-DK	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (DENMARK)	5776689.1	4/8/2005	1756571	8/18/2010		Validated
Klarquist 8123-	REAL TIME METHOD OF	5776689.1	4/8/2005	1756571	8/18/2010		Validated

83101-12-FI	DETECTING ACUTE INFLAMMATORY CONDITIONS (FINLAND)									
Klarquist 8123-83101-13-FR	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (FRANCE)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-14-DE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (GERMANY)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-15-IT	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (ITALY)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-16-LU	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (LUXEMBOURG)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-17-NL	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (NETHERLANDS)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-18-ES	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SPAIN)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-19-SE	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SWEDEN)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-20-CH	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (SWITZERLAND)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-21-GB	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (UNTIED KINGDOM)	5776689.1	4/8/2005	1756571	8/18/2010	Validated				
Klarquist 8123-83101-22-EPC	REAL TIME METHOD OF DETECTING ACUTE INFLAMMATORY CONDITIONS (EPC)	10005450.1	4/8/2005			Pending				
Klarquist 8123-	REAL TIME METHOD OF					Pending				

83101-23-HIK	DETECTING ACUTE INFLAMMATORY CONDITIONS (HONG KONG)								
--------------	---	--	--	--	--	--	--	--	--

SCHEDULE D

Cooley Docket No.	Title	Inventors	Appln. No.	Filing Date	Patent No.	Issue Date	Status
MARKER III (AMPDI, ITPA, IATC, MTR, MTRR)) CYPR- 036/00US PROPR.015A P6008184US P_239HGU	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar; Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	11/400,232	Apr-10-2006	7,713,696 2007023810 3	May-11-2010 Oct-11-2007	ISSUED Expires: Apr-29-2027 (Apr-10-2026 + 384 days) 1 st fee due: May-12- 2014 Filed divisional directed to ITPA
MARKER III CYPR- 036/01US	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar; Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	12/184,184	Jul-31-2008	2009002937 9	Jan-29-2009	PENDING Jul-12-2010 Requirement for Restriction/Election mailed, response due Aug-12-2010 \$3K
MARKER III CYPR- 036/02US	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Guchelaar; Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	12/748,838	Mar-29- 2010			PENDING Awaiting examination
MARKER III P6008184EP	GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY	Not Available Leids Universitair Medisch Centrum	EP application unavailable				ABANDONED
CYPR-040 Family							
MARKER IV [MTHFD1 (or optionally one of AMPDI,	Pharmacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis	Hendrik Guchelaar, Gouda, et al. Academisch	60/840,973	Aug-30- 2006			EXPIRED Converted to Utility application

ATC, (TPA)] CYPR-040/00US P6010832US P_239HGU02		Zeikenhuis H.O.D.N. LUMC								
MARKER IV CYPR-040/01US PROPR.017A	A PHARMACOGENETIC METHOD FOR PREDICTION OF THE EFFICACY OF METHOTREXATE MONOTHERAPY IN RECENT-ONSET ARTHRITIS	Guchelaar, Hendrik Jan; Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	11/846,406	Aug-28-2007	2008028817 7	Nov-20-2008	PENDING Awaiting examination			
MARKER IV CYPR-040/01WO P6010832PCT P_239HGU02	A PHARMACOGENETIC METHOD FOR PREDICTION OF THE EFFICACY OF METHOTREXATE MONOTHERAPY IN RECENT-ONSET ARTHRITIS	Guchelaar, Hendrik Jan Huizinga, Tom Willem Johannes Academisch Ziekenhuis H.O.D.N. LUMC	PCT/NL20 07/050420	Aug-28-2007	2008/026922	Mar-06-2008	SHADOW FILE PENDING National Phase deadline: 2009-02-28			
MARKER IV CYPR-040/00EP P6010832EP P_239HGU02	A PHARMACOGENETIC METHOD FOR PREDICTION OF THE EFFICACY OF METHOTREXATE MONOTHERAPY IN RECENT-ONSET ARTHRITIS	Hendrik GUCHELAAR Academisch Ziekenhuis H.O.D.N. LUMC	06119819.8	Aug-30-2006			SHADOW FILE ABANDONED			
RA PREDICTION/ ALGORITHM I (LUMC) P6008185US P_039THU	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	Huizinga, Tom Willem Johannes; Van Der Helm-Van Mil, Anna Helena Maria None	60/790,531	Apr-10-2006			EXPIRED Converted to Utility application			
RA PREDICTION/ ALGORITHM	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID	Huizinga, Tom Willem Johannes; Van Der Helm-Van Mil, Anna Helena	11/697,665	Apr-06-2007	7,702,469 2007024898 6	Apr-20-2010 Oct-25-2007	ISSUED Expires: May-10-2028 (Apr-06-2027 + 400			

21.

CYPR-039/01US PROPR.016A	ARTHRITIS	ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC	2007/117141 A1	2007/117141 A1	Oct-18-2007	days) 1st fee due: Apr-21-2014
RA PREDICTION/ ALGORITHM CYPR-039/01WO	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	Huizinga, Tom Willem Johannes; Van Der Helm-Van Mil, Anna Helena Maria Academisch Ziekenhuis H.O.D.N. LUMC	PCT/NL20 07/050146	Apr-06-2007	ABANDONED	National Phase deadline 2008-10-07 Instruction sent to LUMC to enter national phase in Europe Canada Australia Japan
RA PREDICTION/ ALGORITHM P6008185EP P_039THU	SYSTEMS AND METHODS FOR PREDICTING AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS	Inventors unavailable Academisch Ziekenhuis Leiden	06112377.4	Apr-07-2006	ABANDONED	

SCHEDULE E

Cooley Docket No.	Title	Inventors	Appl. No.	Filing Date	Patent No.	Issue Date	Status
Orgentec (anti-MCV)	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	PCT/EP2006/006205	Jun-27-2006	2007/000320 A2 2007/000320 A3	Apr-01-2007 Jul-05-2007	CLOSED Entered national stage in: AU 2006263942 CA 2614103 EP 06762214 US (filing receipt to be confirmed) Mexico (To be confirmed)
Orgentec	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	10 2005 029 845.1 2005-06-27	Jun-27-2005	102005029845 A1	Jan-11-2007	PENDING Undergoing preliminary examination Annuity due 2009-06-30 (to be confirmed with Orgentec)
Orgentec	METHOD FOR DIAGNOSTICATING RHEUMATIC DISEASES	Bang, Holger Berg, Wigbert Orgentec Diagnostika GmbH	06762214.2 2006-06-27	Jun-27-2006			PENDING Awaiting examination Annuity due 2009-06-27

SCHEDULE F

Cooley Docket No.	Title	Inventors	Appl. No.	Filing Date	Patent No.	Issue Date	Status
MARKER I CYPR-028/03US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Prometheus Laboratories, Inc.	12/191,287	Aug-13-2008	20090197267	Aug-06-2009	PENDING Awaiting examination
MARKER I CYPR-028/02US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Prometheus Laboratories, Inc.	10/927,904	Aug-26-2004	7,582,282 20050112627	Sep-01-2009 May-26-2005	ISSUED Request for Determination of PTA filed Nov-02-2009 Expires: 2026-03-14 (2024-08-26 + 565 days) 1 st fee due Sep-03-2013 Divisionals filed (RFC-1, ATIC, and TS)
MARKER I CYPR-028/05US	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS	Dervieux, Thierry Walsh, Michael Prometheus Laboratories, Inc.	12/191,286	Oct-29-2008	20090197266	Aug-06-2009	PENDING Awaiting examination
MARKER I CYPR-028/02WO	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACO-GENETICS	Dervieux, Thierry Walsh, Michael Prometheus Laboratories, Inc.	PCT/US2004/ 27851	Aug-27-2004			EXPIRED Entered national stages: EP 04782348.9 CA 2539953
MARKER I CYPR-028/02CA	METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACO-GENETICS	Dervieux, Thierry Walsh, Michael Prometheus Laboratories, Inc.	2539953	Aug-27-2004			EXAM REQUESTED
MARKER I	METHODS FOR OPTIMIZING	Dervieux, Thierry	04782348.9	Aug-27-2004			PENDING

CYPR-028/02EP	CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACO-GENETICS	Walsh, Michael Prometheus Laboratories, Inc.					OFFICE ACTION RESPONSE FILED 7/29/2009 DIVISIONAL DUE 2/3/2011
MARKER II (efficacy: MTHFR, SHMT1, toxicity: ATIC, TSER, and MS)	METHODS FOR EVALUATING RISK ASSOCIATED WITH METHOTREXATE THERAPY USING PHARMACOGENETICS	Dervieux, Thierry Smith, Katie M. Prometheus Laboratories Inc.	60/676,442	Apr-28-2005			EXPIRED Converted to Utility application
CYPR-034/00US							
MARKER II	METHODS FOR MONITORING METHOTREXATE THERAPY USING PHARMACOGENOMIC AND METABOLITE MARKERS	Dervieux, Thierry Prometheus Laboratories Inc.	60/731,598	Oct-27-2005			EXPIRED Converted to Utility application
CYPR-034/01US							
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	11/380,171	Apr-25-2006	20060286571	Dec-21-2006	PENDING Response to Non-Final Rejection filed Feb-22-2010
CYPR-034/02US							Filed divisional directed to SHMT1 (efficacy) and TSER and MS (toxicity)
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	12/194,503	Aug-19-2008			PENDING Awaiting examination
CYPR-034/03US							
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	12/194,501	Aug-19-2008			PENDING Awaiting examination
CYPR-034/04US							
MARKER II	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	PCT/US2006/16246	Apr-26-2006			EXPIRED Entered National Stages: AU 2006239279
CYPR-034/02WO							

MARKER II CYPR-034/02AU	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	20060239279	Apr-26-2006			CA 2606424 EP 06751770.6 EXAM REQUESTED
MARKER II CYPR-034/02CA	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories, Inc.	2606424	Apr-26-2006			REQUEST FOR EXAM DUE 4/26/2011
MARKER II CYPR-034/02EP	METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY	Dervieux, Thierry Prometheus Laboratories Inc.	06751770.6	Apr-26-2006			EXAM REQUESTED
MARKER V (CD30/CD26) CYPR-033/00US	BIOMARKERS ASSOCIATED WITH RESPONSE TO CHEMOTHERAPY	Marcelletti, John F. Dervieux, Thierry Simpson, Lynn A. Prometheus Laboratories, Inc.	10/971,757	Oct-22-2004			ABANDONED Abandoned per JA's email instruction (Oct-14-2009)
MTXPG I (GGH conversion) CYPR-030/00US	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry; Richerson, Russell B. Prometheus Laboratories, Inc.	10/232,760	Aug-30-2002	7,563,590 20040043441	Jul-21-2009 Mar-04-2004	ISSUED Expires: Jan-23-2025 (Aug-30-2022 + 877) 1st fee due Jul-22-2013
MTXPG I CYPR-030/00WO	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	PCT/US2003/ 27313	Aug-28-2003			EXPIRED Entered National Stages: AU 2003270046 CA 2496901 EP 03751939.4
MTXPG I CYPR-030/00AU	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2003270046	Aug-28-2003	2003270046	9/17/2009	REGISTERED

MTXPG I CYPR-030/00CA	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2496901	Aug-28-2003			PENDING OFFICE ACTION RESPONSE FILED 5/27/2010
MTXPG I CYPR-030/00EP	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	03751939.4	Aug-28-2003			PENDING OFFICE ACTION RESPONSE FILED 10/8/2009 DIVISIONAL DUE 4/2/2011
MTXPG I CYPR-030/01AU	METHODS OF QUANTIFYING METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell, B. Prometheus Laboratories, Inc.	2009212945	Aug-28-2003			Divisional of CYPR- 030/00AU OFFICE ACTION ISSUED RESPONSE DUE 10/19/2010
MTXPG II (MTXPG assay) CYPR-032/00US	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	10/384,066	Mar-07-2003	6,921,667 20040175834	Jul-26-2005 Sep-09-2004	ISSUED Expiration date: May-22- 2023 (Mar-07-2023 + 76 days) 1st fee paid 2nd fee due Jul-26-2013
MTXPG II CYPR-032/00WO	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITED	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	PCT/US2004/ 06312	Mar-02-2004			EXPIRED Entered National Stages: AU 2004219711 EP 04716493 JP 2006-508989 CA 2517709
MTXPG II CYPR-032/00AU	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus	2004219711	Mar-02-2004			ALLOWED AWAITING LETTERS PATENT

MTXPG II CYPR-032/00CA	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Laboratories, Inc. Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	2517709	Mar-02-2004	1604203	10/28/2009	REGISTERED Validated in Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Spain, Sweden, Switzerland, United Kingdom
MTXPG II CYPR-032/00EP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00BE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00DK	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00F1	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00FR	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00DE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00JT	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED

MTXPG II CYPR-032/00LU	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00NL	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00ES	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00SE	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00CH	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00GB	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	04716493.4	Mar-02-2004	1604203	10/28/2009	REGISTERED
MTXPG II CYPR-032/00HK	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	06102244.4	Mar-02-2004			PUBLISHED
MTXPG II CYPR-032/00JP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	2006-508989	Mar-02-2004			TAKE NO FURTHER ACTION-TO BE ABANDONED
MTXPG II CYPR-032/01EP	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell	09013484.2	Mar-02-2004			Divisional of CYPR- 032/00EP

MTXPG II CYPR-032/01HK	METHODS FOR DIRECT DETECTION OF INDIVIDUAL METHOTREXATE METABOLITES	Prometheus Laboratories, Inc. Dervieux, Thierry Richerson, Russell Prometheus Laboratories, Inc.	10103341	Mar-02-2004				PUBLISHED PENDING
CYPR-029 Family								
MTXPG III (RFC-I and GGH genotype) CYPR-029/00US	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	60/580,141	Jun-15-2004				EXPIRED Converted To Utility Application
MTXPG III CYPR-029/01US	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	11/152,128	Jun-13-2005	7,695,908 20060057609	Apr-13-2010 Mar-16-2006		ISSUED Expires: Oct-15-2027 (Jun-13-2025 + 854 days) 1 st fee due: Apr-14-2014 PENDING Awaiting examination
MTXPG III CYPR-029/02US	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	12/698,966	Feb-02-2010				PENDING Awaiting examination
MTXPG III CYPR-029/01W0	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	PCT/US2005 /20957	Jun-14-2005				EXPIRED Entered National Stages: AU 2005257949 CA 2591610 EP 05762644.2 JP-2007-516642
MTXPG III CYPR-029/01EP	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratories, Inc.	2591610	Jun-14-2005				PENDING OFFICE ACTION RESPONSE FILED 11/10/2009

									DIVISIONAL DUE 5/12/2011
MTXPG III CYPR-029/01JP	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratoeis, Inc.	2007- 516642	Jun-14-2005					ABANDONED
MTXPG III CYPR-029/01CA	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratoeis, Inc.	2,591,610	Jun-14-2005					EXAM REQUESTED
MTXPG III CYPR-029/01AU	METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACO-GENETICS	Dervieux, Thierry Prometheus Laboratoeis, Inc.	2005257949	Jun-14-2005					OFFICE ACTION ISSUED Response Due 1/20/2011
Compliance Packaging CYPR-031/00US	METHOTREXATE COMPLIANCE PACKAGING	Walsh, Michael J.; Prometheus Laboratories, Inc.	10/384,353	Mar-06-2003	20040176381		Sep-09-2004		ABANDONED
Compliance Packaging CYPR-031/01US	METHOTREXATE COMPLIANCE PACKAGING	Walsh, Michael J.; Prometheus Laboratories, Inc.	11/555,216	Oct-31-2006	20070093497		Apr-26-2007		ABANDONED